Disease · MONDO_0006290

malignant germ cell tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant germ cell tumor. Diseases, record MONDO_0006290. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006290

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant germ cell tumor; Open Targets
Open Targets ID: MONDO_0006290; Open Targets
Other names: cancer of germ cell, germ cell cancer, germ cell tumor, malignant, malignant germ cell neoplasm, malignant neoplasm of germ cell, malignant neoplasm of the germ cell, malignant tumor of germ cell, malignant tumor of the germ cell, malignant tumour of germ cell, malignant tumour of the germ cell; Open Targets
NCI Thesaurus: C4925; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 19 drugs, from ClinicalTrials.gov; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ALISERTIB	CHEMBL483158	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AMIFOSTINE	CHEMBL1006	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	3	Tubulin inhibitor	Phase 2/3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	Phase 2	118	2017-06-05	Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma	ALISERTIB	Its record names the disease	ClinicalTrials.gov
NCT00002931	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer	Phase 2	48	2017-01-04	Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor	CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00467051	Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors	Phase 2	20	2015-03-20	Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor	CARBOPLATIN, IFOSFAMIDE, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00003643	Combination Chemotherapy in Treating Men With Germ Cell Cancer	Phase 2/3	498		Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor	BLEOMYCIN, CISPLATIN, ETOPOSIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03012620	Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types	Phase 2	334		Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm, Carcinoma, Neuroendocrine, Neoplasms, Germ Cell and Embryonal, NK/T-cell Lymphoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00003941	Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer	Phase 3	222		Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor	BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00371553	Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer	Phase 2	33		Relapsed or Cisplatin-Refractory Germ Cell Cancer	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00003811	Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors	Phase 2	27		Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer	AMIFOSTINE, BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00002903	Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer	Phase 2	25		Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor	DOCETAXEL	Its record names the disease	ClinicalTrials.gov
NCT00066482	Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors	Not applicable	19		Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor	BLEOMYCIN SULFATE, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21059637	RESULT	1	PubMed
15999362	RESULT	1	PubMed
37429302	DERIVED	1	PubMed
34435684	DERIVED	1	PubMed
30777875	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006290

GET https://conductscience.org/api/diseases/v1/MONDO_0006290/targets?page=2

API reference For AI assistants